Patient Characteristics and Utilization Patterns of Short-Acting Recombinant Granulocyte Colony-Stimulating Factor (G-CSF) Biosimilars Compared to Their Reference Product

[1]  Shuling Li,et al.  Patterns of granulocyte colony–stimulating factor prophylaxis in patients with cancer receiving myelosuppressive chemotherapy , 2020, Supportive Care in Cancer.

[2]  M. Fisch,et al.  Early Adoption of Biosimilar Growth Factors in Supportive Cancer Care , 2018, JAMA oncology.

[3]  Richard Platt,et al.  The FDA Sentinel Initiative - An Evolving National Resource. , 2018, The New England journal of medicine.

[4]  J. Gagne,et al.  Evaluation of Switching Patterns in FDA’s Sentinel System: A New Tool to Assess Generic Drugs , 2018, Drug Safety.

[5]  C. Dolan,et al.  Opportunities and challenges in biosimilar uptake in oncology. , 2018, The American journal of managed care.

[6]  A. Mulcahy,et al.  Biosimilar Cost Savings in the United States: Initial Experience and Future Potential. , 2018, Rand health quarterly.

[7]  S. Anderson,et al.  The FDA's sentinel initiative—A comprehensive approach to medical product surveillance , 2016, Clinical pharmacology and therapeutics.

[8]  L. Elting,et al.  Granulocyte growth factor use in elderly patients with non-Hodgkin’s lymphoma in the United States: adherence to guidelines and comparative effectiveness , 2016, Supportive Care in Cancer.

[9]  A. Naeim,et al.  Comparative effectiveness of pegfilgrastim, filgrastim, and sargramostim prophylaxis for neutropenia-related hospitalization: two US retrospective claims analyses , 2013, Journal of medical economics.

[10]  M. Zwahlen,et al.  Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients (Review) , 2022 .

[11]  A. Chan,et al.  Impact of colony-stimulating factors to reduce febrile neutropenic events in breast cancer patients receiving docetaxel plus cyclophosphamide chemotherapy , 2011, Supportive Care in Cancer.

[12]  G. Lyman,et al.  Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.